
Editor's Note: The post originally appeared on The Fix, a Pacific Standard partner site. In part one of this investigation, The Fix evaluated Vivitrol's effectiveness. Drugs are commercial products, and drug companies make a profit or die. In the late ‘90s, a Boston biotech called Alkermes picked naltrexone, an anti-craving addiction drug, as its first potential product. Alkermes’ specialty was making extended-release, longer-acting versions of existing drugs. Naltrexone was in dire need of this makeover: Alcoholics and opiate addicts were having a hell of a time taking the daily ... Read More





